搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
FierceBiotech
1 天
Ikena, after tough year of layoffs, merges with Inmagene to focus on phase 2 dermatitis ...
After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a ...
FierceBiotech
1 天
Rapt re-rolls after flameout, paying $35M for challenger to Novartis, Roche drug
A deal with Shanghai Jemincare Pharmaceutical has filled the hole. Rapt is paying $35 million upfront, plus up to $672.5 ...
FierceBiotech
1 天
Editor’s corner: Fierce Medtech’s top 10 stories of 2024 chart the industry’s highs ...
A look back at our top stories of 2024 sees them fall into two major themes: promise, and a realignment of expectations. | A ...
FierceBiotech
1 天
Fierce Biotech's top 10 editor's picks for 2024
The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news ...
FierceBiotech
1 天
FDA approves Humacyte’s off-the-shelf artery implant for vascular trauma repair
The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...
FierceBiotech
1 天
Sanofi pays SK bioscience €50M as children's pneumococcal vaccine enters phase 3
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...
FierceBiotech
1 天
Editor's Corner: Fierce Biotech's 10 most-read stories of 2024
Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. | For the end of this year, ...
FierceBiotech
4 天
Novo Nordisk stock crashes after CagriSema misses phase 3 weight-loss goal
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...
FierceBiotech
1 天
Phase 2 data will drive biopharma VC investments next year: PitchBook
Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according ...
FierceBiotech
4 天
ElectroCore to buy NeuroMetrix and its Quell fibromyalgia wearable stimulator
Nerve stimulation company electroCore has signed an agreement to acquire NeuroMetrix and its Quell wearable device aimed at ...
FierceBiotech
5 天
Regeneron anticoagulant bests enoxaparin, matches Eliquis in phase 2 trial
A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, ...
FierceBiotech
6 天
Ring lays off nearly half of staff, CEO to exit in new year
Flagship CEO-partner and Ring CEO Tuyen Ong, M.D., will also be shifting to an advisory role in the new year, according to ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈